In a double‐blind phase III trial, first‐line sintilimab plus platinum‐based chemotherapy significantly extends PFS and OS in advanced NSCLC lacking EGFR or ALK driver mutations. The gene discussed is ALK; the disease is non-small cell lung carcinoma.